Clinical trial Recruiting at 1 site Observational Ages 21 to 85

VCFix Spinal System in vertebral compression fractures due to osteoporosis

Official title: A Prospective, Multicenter, Post-Market Clinical Study Collecting Real-World Data of the VCFix Spinal System in Stand-Alone Configuration for Vertebral Augmentation (EXPAND-US)

Run by Amber Implants B.V. · NCT07920484 · Data updated 2026-11-12

This study tests the VCFix Spinal System in real-world US patients with vertebral compression fractures from osteoporosis to see how it performs outside a controlled trial.

Quick facts

Study typeObservational
Ages21 Years to 85 Years
SexAll
Enrollment30 (estimated)
SponsorAmber Implants B.V.
Industry-sponsored
Locations3 sites (New York, New York and 2 other locations)
StatusRecruiting
StartedOctober 4, 2026
Main results expectedJuly 21, 2027
Study endsDecember 31, 2028
Registry record updatedNovember 5, 2026
Trial IDNCT07920484 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 21 to 85 with a single thoracic or lumbar vertebral compression fracture meeting specified radiographic and anatomical criteria and with suspected severe osteoporosis.

Probably not a fit

Patients not meeting fracture type, location, timing, or anatomical criteria, or those with contraindicating bone quality or anatomy, may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, post-market, multi-center, single-arm observational study conducted in the United States. Approximately five centers will enroll adults with a single thoracic or lumbar vertebral compression fracture treated with the VCFix Spinal System in its approved use. Data will be collected on safety and clinical performance in routine clinical practice and may be analyzed alongside a European study (EXPAND) if predefined similarity criteria are met. The study aims to provide real-world evidence of effectiveness and safety while aligning methodology with the EU EXPAND study for potential data pooling. Primary endpoints and detailed methods align with the EXPAND framework to enable meaningful comparisons and broader understanding of outcomes in osteoporotic fractures.

Why it matters

Potential benefit: If successful, the study could confirm real-world safety and performance of the VCFix Spinal System in osteoporotic vertebral fractures and support broader clinical confidence and evidence-based use.

How similar studies have gone: The US study is designed to be compatible with the EU EXPAND study to enable data pooling; prior similar approaches have shown value in post-market real-world data for device performance.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1\. Subject is ≥ 21 to ≤ 85 years old. 2.

Single vertebral fracture which meets all of the following criteria:

* Type A fractures from AO spine classification (compression injuries);
* Vertebral fracture located in the thoracic and lumbar regions of the spine
* Fracture age \< 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
* Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
* Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery 3. Subject is diagnosed with, or has a suspected diagnosis of, severe osteoporosis, including low trabecular bone quality , and/or an oversized vertebral body as compared to implant size (e.g. relatively small pedicle requiring smaller implant size than desired for vertebral body size and/or fracture characteristics and location) 4. Subject has a NPRS back pain score of ≥5 5. Subject is a candidate for surgical intervention based on investigator opinion 6. Subject has a body Mass Index (BMI) \< 35 7. Subject is mentally capable of complying with trial protocol requirements for the duration of the study 8. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent

Exclusion Criteria:

1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal
2. Non-mobile fractures (i.e., fracture is not recent (\>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).
3. Spondylolisthesis \> Grade 1 at target vertebral body(s)
4. Local kyphotic angle \> 30°
5. Any pre-existing vertebral fracture prior to the index fracture
6. Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture
7. Subjects that require anterior stabilization of the index fracture
8. Fracture to the pedicle based on radiographic evaluation
9. Spinal cord compression or canal compromise requiring decompression
10. Severe back pain due to causes other than acute fracture with NPRS score \> 5
11. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
12. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication
13. Pre-existing neurological deficit, radiculopathy or myelopathy
14. Pre-existing condition or significant co-morbidity:

    1. Uncontrolled diabetes (HbA1c \>8%)
    2. Severe cardiopulmonary deficiencies
    3. Any other condition that would impact study outcome in the opinion of the investigator
15. Irreversible coagulopathy or bleeding disorder
16. Contraindications to both MRI and Computed Tomography (CT) imaging
17. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study
18. A life expectancy less than the study duration or undergoing palliative care
19. Subject non-ambulatory prior to fracture Allergy to any components of the device/instruments used during the procedure
20. Allergy to any components of the device/instruments used during the procedure
21. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection
22. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)
23. Any evidence of alcohol or drug abuse
24. Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for \>3 months)
25. The subject is currently on anti-cancer therapy or anti-HIV therapy
26. Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration.
27. Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery

Where it's running

  • Montefiore Medical Center
    New York, New York, United States
    Recruiting
  • University of Oklahoma Health Campus
    Oklahoma City, Oklahoma, United States
    Not yet recruiting
  • Rothman Orthopaedics
    Philadelphia, Pennsylvania, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.